Introduction

59
The pathogenesis of pulmonary arterial hypertension (PAH) involves abnormal (vWF) and CD31 proteins, which are endothelial markers, as well as fibronectin and 113 collagen 1 proteins, which are mesenchymal markers, were analyzed at 48 h after 114 stimulation by western blotting to confirm EndMT of the HPMVECs.
115
Proliferation assay of HPASMCs
116
HPASMCs were cultured in Smooth Muscle Growth Medium-2 (SmGM™-2, Lonza). The 117 proliferation of HPASMCs was evaluated using both the Cell Counting Kit-8 (CCK-8) and
118 Bromodeoxyuridine (BrdU) ELISA kit as previously described, respectively (18, 19).
119
HPASMCs were treated with multiple growth factors, specifically 5% fetal calf serum, 120 PDGF-BB (30 ng/mL), FGF2 (2 ng/mL), epidermal growth factor (EGF) (0.5 ng/mL), and 121 insulin-like growth factor-1 (IGF-1) (0.5 μg/mL) with or without imatinib (3 μM) or nintedanib 122 (0.3 μM). The viability of HPASMCs was evaluated time-dependently after stimulation. In 123 advance of this assay, we examined the concentration-dependent inhibitory effects of 124 nintedanib and imatinib, the latter of which is another TKI for PDGF signaling, on the 125 proliferation of HPASMCs induced by PDGF-BB. Based on these preliminary results, we 126 selected 0.3 μM and 3 μM of nintedanib and imatinib, respectively, as concentrations that 127 produced maximum inhibitory effects. LDH assay was also performed to assess the cell 128 toxicity of nintedanib and imatinib as previously described (20) . Value of LDH in the medium 129 with nintedanib and imatinib were normalized by that in the control medium without TKI.
The protein expression of extracellular signal-regulated kinase (ERK)1/2 and AKT with or 131 without phosphorylation, which are downstream effectors of PDGF and FGF signaling, was 132 also evaluated by western blotting at 2 h after stimulation of the HPASMCs.
133
Preparation of pulmonary hypertensive rats
134
The PAH rat model was established using Sugen 5416 (VEGF receptor-1,-2 inhibitor) and 135 chronic hypoxic exposure as previously described (14, 21 
202
Statistical analysis
203
Data are presented as means ± SE. Statistical analysis was performed using one-way 204 ANOVA (Prism 6; GraphPad Software, La Jolla, CA, USA). Differences were considered 205 significant at P < 0.05.
207 Results
208
Inhibitory effect of nintedanib on EndMT of HPMVECs
209
We confirmed decreased expression of vWF and CD31 proteins and increased expression 
215
Inhibitory effect of nintedanib on proliferation of HPASMCs
216
The proliferation of HPASMCs induced by multiple growth factors (PDGF-BB, FGF2, EGF, 217 and IGF) was significantly greater than that without stimulation in CCK-8 and BrdU assays, 218 and nintedanib significantly inhibited this proliferation at 24 and 48 h after stimulation.
Moreover, the inhibitory effect of nintedanib was significantly greater than that of imatinib at 220 48 h after stimulation in CCK-8 assay ( 
226
Chronic treatment with nintedanib in PAH rats
227
The rats were divided into 5 groups as follows: 5-week normoxia + vehicle group [Nx(5W)], EndMT, was higher in human PAH lung than in normal human lung (11). These data 298 indicate a critical contribution of EndMT in the progression of neointimal lesions in PAH.
299
Tyrosine kinase inhibitors for PAH
300
Imatinib is a TKI for Bcr-Abl, c-Kit, c-Abl, and PDGF receptor signaling, and has been used 301 for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors (28).
302
Imatinib was also expected to be a novel anti-vascular treatment for PAH due to its inhibitory 303 effect on PDGF receptor. Imatinib was shown to inhibit the proliferation of HPASMCs from 304 PAs in human PAH (29), and long-term treatment with imatinib prevented the development 305 of chronic hypoxia-and monocrotaline-induced pulmonary hypertension in rats (30, 31) .
306
Furthermore, imatinib combined with various vasodilators significantly improved 6-minute 307 walking distance and pulmonary vascular resistance in human patients, and a phase III 308 clinical study of imatinib for PAH was implemented (32). However, imatinib did not receive final approval for PAH because of its serious adverse effects. Dasatinib, a TKI for Bcr-Abl, 310 c-kit, Src family and PDGF receptor signaling, has been used also to treat chronic 311 myelogenous leukemia. Importantly, dasatinib-induced pulmonary hypertension has been 312 previously reported, suggesting specific toxicity of dasatinib on pulmonary vessels (33, 34). 
343
In HPASMCs, nintedanib also significantly prevented the proliferation induced by multiple 344 growth factors, and the inhibitory effect of nintedanib was significantly greater than that of imatinib after co-stimulation with multiple growth factors. The LDH assay showed no 346 difference even after treatment with nintedanib, suggesting no toxicity of nintedanib for 347 HPASMCs. ERK1/2 and AKT, which are downstream effectors of PDGF and FGF signaling, 348 play roles in the regulation of vascular smooth muscle cell proliferation and apoptosis.
349
Nintedanib also remarkably reduced the phosphorylation of ERK1/2 and AKT after 350 co-stimulation, and this inhibitory effect of nintedanib was greater than that of imatinib.
351
These in vitro results suggest a beneficial, anti-remodeling effect of nintedanib in the intima 352 and media of PAs in PAH.
353
Effect of nintedanib in vivo
354
Classical animal models of pulmonary hypertension that are induced by chronic hypoxic 355 exposure and monocrotaline have no neointimal lesions in the small PAs. Hence, these 356 models were considered inappropriate for the study of PAH. In the present study, we used 
387
A recently published study demonstrated that nintedanib had no therapeutic effect on rat 388 and human PAH (44), which contradicted our results. Several factors could explain the 389 discrepancy between the studies. For instance, rat strain that were used for experimental 390 PAH were different. A previous report has shown that the severity of the response to 391 Sugen5416 with hypoxic exposure was remarkably different between rat strains (45).
392
Actually, the RVSP of SuHx PAH in Wistar-Kyoto rats was obviously lower in a recent study 393 than in this study. Therefore, the response to nintedanib also may be dissimilar between 394 strains. As another factor, muscularization of the small PAs was evaluated to assess the 395 effect of nintedanib in a recent study. Such measurement is common for hypoxic or 396 monocrotaline-induced pulmonary hypertension models that have no neointimal lesions, but 397 it is not appropriate for the SuHx PAH rat which has neointimal lesions in the small PAs. In 398 addition, pathological images of small PAs were not shown in that study; thus, it is unclear greater than that of large proximal PA in the disease progression of PAH. Thus, data would 418 be more useful by using HPASMC isolated from only small distal PA. Third, the mechanism 419 of the inhibitory effect of nintedanib on EndMT progression is still unclear. We induced 
